Resonant Medical announces new CEO, VP Strategic Marketing and Chairman of the Board of Directors

    MONTREAL, May 23 /CNW Telbec/ - Resonant Medical Inc. announced today the
addition of three experienced business leaders from the fields of medical
equipment and radiation oncology to senior positions of the Company's
Leadership Team.
    Steven G. Arless has been appointed to the position of President and CEO.
The Company's co-founder, Fred Francis, who served as Resonant's President and
CEO since the Company's inception, will remain as Executive Vice-President of
Corporate Development.
    "Resonant Medical has developed innovative ultrasound-based IGRT
technologies used during both the planning and treatment of various cancers
with radiation", commented Mr. Arless. "I am excited to join this dynamic
company at this stage in its growth."
    "Steve has a proven track record in medical equipment and we welcome him
to the team. As a seasoned CEO, he will help the Company realize its market
potential in the field of image guided radiation therapy", explained Frederic
    The Company also announced that Alfred J. Lawson, Ph.D. has joined the
company as Vice-President of Strategic Marketing. Mr. Lawson has an extensive
clinical background and experience in the commercialization of radiation
oncology technologies.
    Finally, William E. Curran, a former executive at Philips Medical Systems
and Philips Electronics N.A., has been elected as Chairman of the Board of
Directors, replacing John C. Ford, a 30 year radiation oncology industry
veteran and former top executive of Varian Medical Systems. Mr. Ford will
continue to serve on the Board of Directors.
    "It is a privilege to work with such a group of experienced executives",
commented Mr. Curran. "We wish to thank John for his invaluable service to the
Company and look forward to his continued contribution."

    Short biographies

    Mr. Arless has over 35 years experience in the development, marketing and
sales of medical devices products, most recently at CryoCath as President and
Chief Executive Officer, and at Smith & Nephew Inc. where he served as
President. Mr. Arless serves on the Board of Directors of a number of medical
devices companies and professional Medical and industrial associations, as
well as the Advisory Boards of both McGill University's Faculty of Science,
and Concordia University's John Molson School of Business.
    Alfred J. Lawson, Ph.D., previously worked at Varian Medical Systems.
Mr. Lawson has also served as administrative director of a number of Radiation
Oncology programs in Florida and Tennessee, a faculty member of the University
of Alabama School of Medicine and Comprehensive Cancer Center in Birmingham,
and clinical adjunct professor of Radio-biology at the University of Tennessee
Center for Health Sciences in Memphis.
    William E. Curran is a former executive of Philips, a leading
manufacturer of systems for diagnostic imaging, oncology treatment planning
and patient monitoring as well as provider of information management and other
medical products. He held a number of senior management positions in Philips'
medical business and served as CFO and CEO of Philips Electronics North
    John C. Ford Ph.D. is a recognized expert in medical technology,
radiation and medical physics, and radiation oncology. Dr. Ford is a former
executive of Varian Medical Systems where he served as President of Varian
International Marketing, Senior Vice President of Oncology Systems Division,
and Senior Scientist.

    About Resonant Medical and RESTITU(TM)

    Resonant Medical Inc. is a leader in the research, development and
marketing of 3D ultrasound image-guided radiotherapy products designed to
improve treatment planning, verification and delivery of radiotherapy
treatment for patients with breast, head & neck, cervix, bladder, and other
soft tissue malignancies.
    The RESTITU(TM) Platform accurately visualizes and corrects daily changes
in tumor position, shape and size, for radiotherapy treatment planning and
image guidance. Installed in CT-Sim rooms, RESTITU U/S-SIM(TM) allows for
better definition of planning tumor volumes with its patented IMPLICIT
REGISTRATION(TM) technology that automatically fuses 3D U/S to CT data. With
U/S-SIM, multimodality treatment planning has now been made possible and
affordable for all clinics, with or without PET or MRI. Installed in treatment
rooms, RESTITU U/S-GUIDE(TM) allows for highly accurate patient position
verification and alignment, with its proprietary MUTUAL REFERENCING(TM)
technology that uses assisted segmentation for efficient and robust
intramodality 3D U/S image-guidance.

For further information:

For further information: Luc Sirois, Chief Operation Officer, Resonant
Medical, M.: (514) 518-0449, (514) 985-2442 x 267,

Profil de l'entreprise


Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.